United States: JTEKT V GKN: Lacking Standing, Competitor Cannot Appeal PTAB IPR Ruling

The Federal Circuit further restricted a petitioner's ability to appeal a decision by the Patent and Trademark Appeal Board upholding the validity of a patent. The court this month found in JTEKT v. GKN Automotive that a competitor who filed a petition for inter partes review could not appeal the PTAB's validity determination because its product design was not definite enough to create a concrete and substantial risk of infringement or the likelihood of a claim of infringement. If this line of decisions stands, it will make it harder for competitors to clear the field of conflicting patents that they believe are invalid, as there would be no ability to appeal from an adverse Board decision.

PTAB Post Grant Decisions and Standing to Appeal Them

In the past year and a half, the Federal Circuit has grappled with the rights of petitioners to appeal decisions by the PTAB in post grant proceedings, such as post grant review and inter partes review, under the America Invents Act. Congress established the expanded review proceedings of the AIA to reduce the cost of testing the validity of a dubious patent that could disrupt product development in a field of technology for years. In testimony accompanying draft legislation for post grant review submitted by the American Intellectual Property Law Association, the association's director raised concerns that under pre AIA law, a potential competitor could only test a patent's validity through litigation if the patentee brings an infringement action or threatens to do so. A competitor could not challenge a patent in litigation before the competitor incurs the costs and risks of developing and marketing a potentially infringing product. (SeeMatal, " A Guide to the Legislative History of the America Invents Act.") The post-AIA review proceedings serve another purpose as well. As stated by the Supreme Court in Cuozzo Speed Technologies v. Lee, "[t]he purpose of inter partes review is not only to resolve patent-related disputes among parties, but also to protect the public's 'paramount interest in seeing that patent monopolies... are kept within their legitimate scope.'"

In Consumer Watchdog v. Wisconsin Alumni Research Foundation, the Federal Circuit held that the statutory grant of the ability to appeal a Board decision does not automatically grant standing in the Court of Appeals. It first confronted the issue of standing in appeals from PTAB decisions in IPR in Phigenix v. Immunogen. After recognizing that in the 35 years since the Federal Circuit court's inception, it had not established the legal standard for demonstrating standing in an appeal from a final agency action, the court found that Phigenix had not met its burden of proving standing to appeal. A declaration submitted by Phigenix stating that the existence of the patent had encumbered licensing efforts and a letter highlighting concerns over the patent's validity from its own attorney did not in the Federal Circuit's view constitute sufficient facts to support Phigenix's claim that it had suffered an actual economic injury due to increased competition between itself and the patent holder.

Since Phigenix, the court has twice found that an appellant claiming harm due to fear of a potential infringement action did have standing to appeal an adverse PTAB decision. In PPG Industries v. Valspar Sourcing the court held that since PPG already had launched a commercial product and had received an inquiry from a customer concerned about Valspar's patent, PPG did have standing. (The court may have been influenced by the infringement suit filed by Valspar soon after PPG filed its appeal.) In contrast to Phigenix, in May 2018 the court in Altaire Pharmaceuticals v. Paragon Bioteck cited testimony by Altaire's general counsel concerning the imminence of Paragon's infringement suit as well as testimony that Altaire intended to file an Abbreviated New Drug Application—or ANDA—if Paragon terminated its joint development agreement with Altaire in support of its decision finding standing for Altaire to appeal.

JTEKT and Whether Competitive Harm Gives Rise to Standing

In JTEKT, the Federal Circuit had another opportunity to consider whether current competitive harm, rather than fear of potential infringement suits, constitutes an injury in fact for the purposes of deciding whether an appellant has standing to appeal a PTAB decision. JTEKT, a Toyota subsidiary, petitioned for IPR of seven claims of GKN's patent. The PTAB upheld the validity of two of the seven claims, and JTEKT appealed the decision to the Federal Circuit.

While the JTEKT panel relied on Phigenix in concluding that JTEKT did not have standing, its ruling was actually an extension of the Phigenix holding. In Phigenix the panel found that the petitioner had not presented facts to support its claim of an economic injury due to increased competition. However, the decision in JTEKT goes further, stating that economic injury due to increased competition, even if supported by the facts, is not enough to establish standing to appeal a decision of the PTAB. Because of this conclusion, the panel in JTEKT gave no weight to JTEKT's claim of competitive harm and turned to the question of whether JTEKT had proffered adequate evidence that it had suffered an injury based on potential infringement liability. The court held that where a party is not currently engaging in infringing activity, the party must establish that it has concrete plans for future activity that create a substantial risk of future infringement or would likely cause the patentee to assert a claim of infringement. The Federal Circuit panel found that because JTEKT's product was not yet finalized, JTEKT did not have standing to appeal. It further concluded that the estoppel provisions of the AIA regarding post grant proceedings did not create an injury in fact when JTEKT had not to date engaged in any activity that would give rise to a possible infringement suit.

In requiring a petitioner to show concrete plans for future potentially infringing activity, the Federal Circuit seems to be reverting to its "reasonable apprehension of suit" test for Article III standing that was rejected by the Supreme Court in Medimmune v. Genentech. This brewing conflict likely will come to a head in another case currently before the Federal Circuit concerning standing in appeals from PTAB decisions in post grant proceedings. Oral arguments heard on December 5, 2017 in the pending case, Momenta Pharmaceuticals v. Bristol-Myers Squibb, exclusively addressed the issue of standing. Bristol-Myers Squibb argued that Momenta did not have standing until it filed an abbreviated biologics license application to the U.S. Food and Drug Administration for its biosimilar drug. Momenta argued that it was presently harmed because the PTAB's adverse decision had forced it to make a decision to either continue on its current path and infringe the patent in the future, or to "work around" the claims of the patent. In its argument, Momenta asserted that the hypothetical question of whether Momenta would have Article III standing to bring a declaratory judgment proceeding is not relevant because in an appeal from an agency action there is no question of ripeness. Despite this assertion, Judge Pauline Newman analogized to the Federal Circuit's recent decision in Sandoz v. Amgen, holding that there was no case or controversy because "the only activity that would create exposure to potential infringement liability was a future activity requiring an FDA approval that had not yet been sought." Judge Newman continued that the issue of Article III standing applies to both a declaratory judgment action and to an appeal from a PTAB decision and that the Sandoz "precedent is against [Momenta], strongly." The judges' questions emphasized that despite Momenta's concession that the product in trials infringed Bristol-Myers Squibb's patent, a long chain of contingencies stood between a product in trials and one that would lead to infringement of the patent by Momenta.

In contrast to the Federal Circuit's reluctance to recognize increased competition or increased development costs caused by a PTAB decision as an injury in fact for purposes of Article III standing, other courts presented with appeals of administrative proceedings have acknowledged that competitive injury can establish standing in an Article III court. The Supreme Court in Association of Data Processing Service Organizations v. Camp found that a data processing service had standing to challenge a ruling by the Office of the Comptroller of the Currency that national banks may make data processing services available to bank customers and other banks. The Court recognized that the petitioners had sufficiently satisfied the "injury in fact" test by alleging that "competition by national banks in the business of providing data processing services might entail some future loss of profits for the petitioners... ." Similarly the D.C. Circuit Court of Appeals (a court which addresses so many appeals from administrative decisions that it has local rules to address the issue) in First National Bank & Trust v. National Credit Union, found that four banks had standing to challenge the National Credit Union Administration's approval of applications to expand a credit union's membership. "[N]o one questions appellants' Article III standing; that appellants will suffer competitive or economic injury is not in doubt." See also Liquid Carbonic Industries v. FERC ("Increased competition represents a cognizable Article III injury.")

Why JTEKT Matters?

The Federal Circuit's decision in JTEKT rejects the notion that an economic injury due to increased competition from a patent holder can establish standing in appeals to the Federal Circuit. Such decisions denying standing from adverse decisions of the PTAB disproportionately affect patent challengers. Presumably, a decision by the PTAB invalidating a patent would cause a patent owner a concrete and particularized injury, and therefore the patent owner would be granted an automatic right to appeal. As discussed above, this is not the case for a patent challenger. A competitor who wishes to avoid incurring the costs and risks of developing and marketing a potentially infringing product before having an opportunity to challenge the validity of a patent, as Congress intended, pays a price. As a Federal Circuit judge noted during oral argument of the Momenta case, the estoppel provision of the AIA post grant proceedings "makes it a pretty good situation" for patent holders. Industry competitors must choose between filing a petition for review of a patent before the PTAB, potentially forever losing their day in an Article III court, or investing significantly in product development before making any challenge to a patent in order to file a declaratory judgment action or be poised to appeal an adverse decision by the PTAB.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
20 Sep 2018, Other, California, United States

CoinAlts is designed to bring together the thought leaders in the cryptocurrency investment space to discuss the investment, legal and operational is​sues for cryptocurrencies as a new asset class.

25 Sep 2018, Conference, California, United States

We're excited to introduce Women's IP Strategy, a 2-day conference that tackles both the IP, legal as well as broader career development obstacles, risks and rewards for women lawyers working in male-dominant industries.

2 Oct 2018, Webinar, California, United States

This CLE webinar will offer suggestions to litigators to help them comply with the new GDPR during e-discovery.

Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions